This article is a Preprint
Preprints are preliminary research reports that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Preprints posted online allow authors to receive rapid feedback and the entire scientific community can appraise the work for themselves and respond appropriately. Those comments are posted alongside the preprints for anyone to read them and serve as a post publication assessment.
Immunogenicity of DNA vaccine encoding spike protein against Middle East respiratory syndrome coronavirus in mammalian model (preprint)
researchsquare; 2024.
Preprint
in English
| PREPRINT-RESEARCHSQUARE | ID: ppzbmed-10.21203.rs.3.rs-3890698.v1
ABSTRACT
Background:
The Middle East respiratory syndrome coronavirus (MERS-CoV) is currently a major threat to public health worldwide. There are, as of yet, no licensed MERS-CoV vaccines or therapeutics. The rapid development and deployment of low-cost and effective vaccines against emerging variants has renewed interest in DNA vaccine technology. So, the aim of the current study is the generation and immunological evaluation of DNA vaccine candidates against MERS-CoV.Methods:
The spike gene was selected to generate the DNA vaccine, which encodes the spike protein of coronaviruses that plays a pivotal role in viral entry into host cells and serves as a primary target for host immune responses. Moreover, the antibody responses post-immunization with spike-DNA fragment and inactivated coronaviruses vaccines was explored, using a microneutralization assay with severe acute respiratory syndrome (SARS-CoV-2), and the log2 antibody titers at different time points (0, 2, 4, 6, and 8 weeks) post-vaccination was measured.Results:
The inactivated MERS-CoV and pCDNA3.1-S-MERS-CoV vaccines maintained steady log2 antibody titers, showing no specific response to SARS-CoV-2 in the control group (PBS). Microneutralization against MERS-CoV showed no significant antibody titers for Inactivated SARS-CoV-2, suggesting no cross-reactivity. Sustained antibody titers for Inactivated MERS-CoV indicate vaccine-induced stability.Conclusion:
This study sheds light on antibody responses induced by these vaccines against MERS-CoV, aiding rapid development and deployment of low-cost and effective vaccines. These insights are crucial for optimizing vaccine strategies, particularly in the context of the evolving MERS-CoV pandemic.
Full text:
Available
Collection:
Preprints
Database:
PREPRINT-RESEARCHSQUARE
Main subject:
Respiratory Insufficiency
/
Coronavirus Infections
/
Severe Acute Respiratory Syndrome
Language:
English
Year:
2024
Document Type:
Preprint
Similar
MEDLINE
...
LILACS
LIS